Infection Leading Articles & Analysis

The Native Antigen Company Limited (‘NAC’: Oxford, UK) announces the launch of a new range of Dengue Virus-Like Particles incorporating products for all four Dengue serotypes. Virus-Like Particles (VLPs) represent an increasingly important technology for use in vaccine development and serology. VLPs consist of protein shells comprising outer proteins specific to the virus in ...

By The Native Antigen Company

The British Occupational Hygiene Society (BOHS), the Chartered Society for Worker Health Protection has strongly endorsed the findings in a comprehensive report by the Healthcare Safety Investigation Branch (HSIB). The report, published today, aims to understand the factors that could contribute to the risk of COVID-19 transmission in the NHS and where there may be opportunities to reduce that ...

By The British Occupational Hygiene Society (BOHS)

Nob Hill Therapeutics was selected as a finalist in the Redefining Early Stage Investments (RESI) Innovator’s Pitch Challenge (IPC). An opportunity for early-stage companies to gain exposure to conference attendees, pitch directly to a panel of relevant investors, and participate in a live Q&A session. The IPC focuses on early-stage life science companies actively raising capital and ...

By Nob Hill Therapeutics

The environmental and infection control experts at EC2 provide prevention services, inspections and solutions for healthcare facilities battling C. diff threats. Just last week it was reported that an outbreak of C. difficile (C. diff) at a Canadian hospital has already infected 63 patients. The outbreak has caused at least one confirmed death and possibly six others. This latest ...

By Cochrane & Associates, LLC

Abionic SA, a developer of disruptive nanotechnology based rapid diagnostic solutions, announced today the successful completion of its multi-center observational study using Abionic’s novel point-of-care Pancreatic Stone Protein (PSP) sepsis test on the abioSCOPE® platform. The results of the study show an anticipation of 24 hours for the diagnosis of sepsis compared to current ...

By Abionic SA

Methicillin-resistant Staphylococcus Aureus (MRSA) is a type of staph bacteria that is resistant to certain antibiotics known as beta-lactams. These antibiotics include methicillin and other more common antibiotics such as oxacillin, penicillin, and amoxicillin. In the community, most MRSA infections are skin infections. Last month, Time Magazine published a story about the rise of ...

By Cochrane & Associates, LLC

Groningen, the Netherlands - 3 February 2017 - ViciniVax, a Dutch biopharmaceutical company in Groningen, announced today the treatment of the first patient with Vvax001 in a Phase I study in patients with a history of cervical intraepithelial neoplasia (CIN) 2 and 3 or cervical cancer. The Phase I study is an investigator-initiated Phase I clinical trial conducted by the Department of Obstetrics ...

By ViciniVax BV

Results show a single, 5-minute treatment of nasal photodisinfection significantly reduces Staphylococcus aureus, a major cause of surgical site infections, in pre-surgical patients Top line results met primary endpoint and showed nasal photodisinfection eliminated or significantly decreased Staphylococcus aureus ( aureus) in 92% of carriers treated per protocol (P<0.001). All of the 319 ...

By Ondine Biomedical Inc

PreHevbri is the only approved 3-antigen hepatitis B vaccine for adults in the United Kingdom Approval follows the European Commission’s marketing authorisation, granted in April 2022 VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that the UK Medicines and ...

By VBI Vaccines Inc.

Clinical Infectious Diseases recently published a study that discovered azole-resistance markers in 75% of a small group of aspergillosis patients who had not previously been treated with an azole. Although the study group was small, the findings appear to indicate that there is a growing dissemination of drug-resistant strains of Aspergillus fungi. Azole antifungal agents are a common option ...

By Cochrane & Associates, LLC

Countless people live productive and fulfilling lives with immune systems that are weakened due to inherited genetic defects, physical conditions, illnesses, past medical procedures or because of prescription drugs taken for various reasons. These individuals need to be especially aware of common microbial pathogens that are often found all around us. These pathogens may include various ...

By Clark Seif Clark Inc.

Today DNV GL announced a new certification program aimed at transforming hospitals’ approach to managing infection risk. DNV GL certified Sentara Leigh and Sentara Virginia Beach General Hospitals in Virginia as the first two Centers of Excellence for its Managing Infection Risk (MIR) Certification, recognizing exceptional processes and an approach to mitigating infection risk that exceeds ...

By DNV GL - Business Assurance North America

Intersect ENT®, Inc. (Nasdaq: XENT), a global ear, nose and throat (“ENT”) medical technology leader dedicated to transforming patient care, today announced the U.S. nationwide commercial availability of the VenSure™ Balloon Sinus Dilation System and Cube™4D Navigation System with VirtuEye™ photo registration. The VenSure Balloon and Cube 4D Navigation Systems ...

By Intersect ENT, Inc.

In October, the Columbia University School of Nursing published a news release about a study that found rising infection rates at nursing homes across the country. After examining infections in nursing homes in the United States over a 5 year period, the study concluded that rates of a variety of infections are increasing, including those caused by multiple drug-resistant organisms (MDROs). ...

By Cochrane & Associates, LLC

Dynavax expects year over year revenue growth for HEPLISAV-B and CpG 1018 adjuvant to drive continued profitability in 2022 Strong financial position supports investment in long-term growth drivers including pipeline expansion Initiation of Phase 1 clinical trial of shingles vaccine candidate, adjuvanted with CpG 1018, with data expected year end 2022 Dynavax Technologies Corporation ...

By Dynavax Technologies Corporation

The National Institute of Allergy and Infectious Diseases (NIAID), an agency of the National Institutes of Health (NIH), has awarded a Phase I, $300,000 Small Business Innovative Research (SBIR) contract to Kephera Diagnostics to develop a new test for Chagas disease, the company announced today. The contract, awarded in response to a targeted solicitation from NIAID aimed at improving ...

By Kephera Diagnostics, LLC

Aurealis Therapeutics, a private clinical-stage biopharmaceutical company developing AUP-16, the three-in-one combination biologic drug for chronic non-healing wounds and regenerative diseases, announced today that the first diabetic foot ulcer (DFU) patient has been dosed with AUP-16. The trial is performed in non-healing DFU patients and is designed to evaluate the safety, tolerability and ...

By Aurealis Therapeutics

Last month, Fox News published a report about a cosmetic surgery center that was shut down by Maryland health officials. The closure resulted after several patients developed infections and one tragically died. According to the report, there were issues in standard inspection control that caused health officials to order the facility’s closure. The illnesses were caused by invasive ...

By Sussex Environmental Health Consultants

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease, today announced that John Dillman has been appointed as the Company’s Chief Commercial Officer. Mr. Dillman will be responsible for leading VBI’s commercial strategy, sales, and sales operations, including the commercialization of ...

By VBI Vaccines Inc.

CARB-X is awarding Accelerate Diagnostics, a Tucson, Arizona, USA, biotech company, up to US$578,000 to develop new fiber optic technology to diagnose sepsis or the risk of sepsis. Accelerate would be eligible for up to $2.1 million in additional funds from CARB-X if the project meets certain milestones, subject to available funds. Sepsis is the body’s overwhelming and life-threatening ...

By Accelerate Diagnostics, Inc.